Clinical Trials Arena on MSN
Agomab’s ALK5 inhibitor to advance to Phase IIb in Crohn’s disease
Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...
Macrophages can alternate between two states: an inflammatory state for fighting infection and a non-inflammatory state for ...
14h
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment -- -- Pharmacokinetic results confirm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback